AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14667946 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking backwards on a soft surface
Number of subjects: 11
Study 10750541 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about negative events
Number of subjects: 0
Study 10750541 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about nonemotional events
Number of subjects: 0
Study 10750541 — intervention group
Group type: COMPARATOR
Intervention: Non-writing control group
Number of subjects: 0
Study 8782754 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (prednisolone reduced to zero over about four months)
Number of subjects: 100
Study 8782754 — intervention group
Group type: COMPARATOR
Intervention: Control (maintaining triple immunosuppression unchanged)
Number of subjects: 100
Study 8782754 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 100
Study 8782754 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 1352363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 400 mg/kg every 28 days
Number of subjects: 376
Study 1352363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 376
Study 6424580 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced Hypertension Chemotherapy (IHC) with a three-drug regimen (adriamycin, 5-FU, mitomycin C or adriamycin, vincristine, carboquone)
Number of subjects: 102
Study 6424580 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced Hypertension Chemotherapy (IHC) for stomach cancer
Number of subjects: 102
Study 6424580 — intervention group
Group type: COMPARATOR
Intervention: Control group for stomach cancer
Number of subjects: 102
Study 31826896 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle group sessions (9 weekly sessions)
Number of subjects: 43
Study 31826896 — intervention group
Group type: COMPARATOR
Intervention: Family voucher for a leisure centre (control)
Number of subjects: 43
Study 30173303 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 60
Study 30173303 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine
Number of subjects: 60
Study 30173303 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS)
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Full-fat milk
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Skimmed milk
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Cola
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Diet cola
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Hot tea
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Iced tea
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Coffee
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Lager
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Sparkling water
Number of subjects: 72
Study 26702122 — intervention group
Group type: COMPARATOR
Intervention: Sports drink
Number of subjects: 72
Study 26702122 — intervention group
Group type: EXPERIMENTAL
Intervention: Still water
Number of subjects: 72
Study 24745692 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy in addition to home exercise program (18 days)
Number of subjects: 214
Study 24745692 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program alone
Number of subjects: 214
Study 22594581 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated GFR (eGFR) below 45 mL/min/1.73 m(2)
Number of subjects: 4016
Study 22594581 — intervention group
Group type: COMPARATOR
Intervention: eGFR above 45 mL/min/1.73 m(2)
Number of subjects: 4016
Study 19808060 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Attend CS+ (attended stimulus followed by aversive US)
Number of subjects: 0
Study 19808060 — intervention group
Group type: COMPARATOR
Intervention: Group Attend CS- (ignored stimulus paired with aversive US)
Number of subjects: 0
Study 19808060 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aversive reaction time task (Experiment 2)
Number of subjects: 0
Study 17629203 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-based group (Group T)
Number of subjects: 3
Study 17629203 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents-based group (Group P)
Number of subjects: 3
Study 17629203 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 3
Study 15128684 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing visit
Number of subjects: 100
Study 15128684 — intervention group
Group type: COMPARATOR
Intervention: Postal distribution of a guideline for prescribing asthma medication
Number of subjects: 100
Study 11771023 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle repositioning manoeuvre (PRM)
Number of subjects: 71
Study 11771023 — intervention group
Group type: COMPARATOR
Intervention: Sham PRM
Number of subjects: 71
Study 11771023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 9591542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 50 mg/kg intravenously
Number of subjects: 25
Study 7997065 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extractum (GBE) 160 mg/d combined with memory training
Number of subjects: 0
Study 7997065 — intervention group
Group type: COMPARATOR
Intervention: Piracetam 2.4 or 4.8 g/d combined with memory training
Number of subjects: 0
Study 7997065 — intervention group
Group type: COMPARATOR
Intervention: Piracetam 3.3 g/d combined with normal school teaching and logopedic therapy
Number of subjects: 0
Study 7997065 — intervention group
Group type: COMPARATOR
Intervention: Piracetam 4.8 g/d combined with speech therapy
Number of subjects: 0
Study 3276453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine infusion (10, 30, and 50 micrograms/kg/min for 6 min each)
Number of subjects: 7
Study 3276453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 7
Study 29239230 — intervention group
Group type: EXPERIMENTAL
Intervention: Scribe implementation (post-scribe cohort)
Number of subjects: 12671
Study 29239230 — intervention group
Group type: COMPARATOR
Intervention: Pre-scribe cohort
Number of subjects: 12671
Study 31434390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP + moderate intensity aerobic exercise
Number of subjects: 112
Study 31434390 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 112
Study 31434390 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Number of subjects: 112
Study 28991914 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100mg)
Number of subjects: 23
Study 28991914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol)
Number of subjects: 23
Study 25315383 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX 50 mg/m(2) administered as a single intramuscular dose)
Number of subjects: 23
Study 25315383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution administered in a single intramuscular dose)
Number of subjects: 23
Study 25315383 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 23
Study 25315383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23721034 — intervention group
Group type: COMPARATOR
Intervention: Basic preventive program (dietary counselling, oral hygiene instructions, fluoride varnish application)
Number of subjects: 160
Study 23721034 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel in trays (additional measure)
Number of subjects: 160
Study 23721034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NaF gel in trays (additional measure)
Number of subjects: 160
Study 23721034 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tooth brushing with 1% chlorhexidine gel (additional measure)
Number of subjects: 160
Study 21964172 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 (orally inhaled dihydroergotamine)
Number of subjects: 902
Study 19148734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral human immunoglobulin (IGOH) 140, 420, or 840 mg/day
Number of subjects: 125
Study 19148734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16772757 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-U BTX‐A
Number of subjects: 32
Study 16772757 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 32
Study 16330680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated-fat diet
Number of subjects: 1062
Study 16330680 — intervention group
Group type: COMPARATOR
Intervention: Control (unrestricted diet)
Number of subjects: 1062
Study 12194548 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 cm alimentary limb (Group A)
Number of subjects: 110
Study 12194548 — intervention group
Group type: COMPARATOR
Intervention: 150 cm alimentary limb (Group B)
Number of subjects: 110
Study 12194548 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 cm alimentary limb (Group C)
Number of subjects: 110
Study 12194548 — intervention group
Group type: COMPARATOR
Intervention: 250 cm alimentary limb (Group D)
Number of subjects: 110
Study 9576972 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH(1‐34)
Number of subjects: 0
Study 9576972 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH and estrogen combination
Number of subjects: 0
Study 9576972 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH treatment
Number of subjects: 0
Study 7872170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ECG testing
Number of subjects: 191
Study 2241053 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital block
Number of subjects: 62
Study 2241053 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration
Number of subjects: 62
Study 795438 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mug/kg delta‐9‐trans‐tetrahydrocannabinol (delta‐9‐THC) p.o.
Number of subjects: 36
Study 795438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 795438 — intervention group
Group type: EXPERIMENTAL
Intervention: delta‐9‐THC
Number of subjects: 36
Study 31357273 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR FTIR spectroscopy with chemometric modeling for analysis of HMF in honey
Number of subjects: 0
Study 31357273 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration and modeling efforts for ATR FTIR spectroscopy
Number of subjects: 0
Study 27922285 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter alone
Number of subjects: 108
Study 27922285 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter plus oxytocin
Number of subjects: 108
Study 27922285 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 108
Study 26083546 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reduction group (target LDL-C reduction achieved within 4 weeks)
Number of subjects: 427
Study 26083546 — intervention group
Group type: COMPARATOR
Intervention: Late reduction group (target LDL-C reduction not achieved within 4 weeks)
Number of subjects: 427
Study 26083546 — intervention group
Group type: COMPARATOR
Intervention: Late reduction group
Number of subjects: 427
Study 26083546 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reduction group
Number of subjects: 427
Study 26083546 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent reduction of LDL-C level during the initial 4 weeks
Number of subjects: 427
Study 26083546 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LDL-C level
Number of subjects: 427
Study 23551950 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus 0.1% ointment
Number of subjects: 20
Study 23551950 — intervention group
Group type: COMPARATOR
Intervention: mometasone furoate cream
Number of subjects: 20
Study 21592994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART and 1-month C-reactive protein (CRP) levels
Number of subjects: 189
Study 21592994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART and 1-month D-dimer levels
Number of subjects: 189
Study 21592994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART and 1-month interleukin 6 (IL-6) levels
Number of subjects: 189
Study 21592994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART hyaluronic acid (HA) levels
Number of subjects: 189
Study 21592994 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels above cohort median (>2.1 mg/L)
Number of subjects: 189
Study 21592994 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HA levels above cohort median (>50.0 ng/mL)
Number of subjects: 189
Study 21592994 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with immune reconstitution inflammatory syndrome (IRIS) events
Number of subjects: 189
Study 19429065 — intervention group
Group type: EXPERIMENTAL
Intervention: BT-11
Number of subjects: 0
Study 19429065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16903879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate‐mefloquine (AM)
Number of subjects: 220
Study 16903879 — intervention group
Group type: COMPARATOR
Intervention: Oral dihydroartemisinin‐piperaquine (DP)
Number of subjects: 220
Study 15007110 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily (intensive therapy)
Number of subjects: 4162
Study 15007110 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of pravastatin daily (standard therapy)
Number of subjects: 4162
Study 11729943 — intervention group
Group type: EXPERIMENTAL
Intervention: Live graded exposure (LGE)
Number of subjects: 28
Study 11729943 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided vicarious exposure (CAVE)
Number of subjects: 28
Study 11729943 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 28
Study 9868115 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine and western medicine
Number of subjects: 88
Study 9868115 — intervention group
Group type: COMPARATOR
Intervention: Regular medicine
Number of subjects: 88
Study 9868115 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal cavity administration
Number of subjects: 88
Study 7869017 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation treatment after October 1985
Number of subjects: 193
Study 7869017 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiotherapy and fat soluble chemotherapy (not utilized in earlier cases)
Number of subjects: 193
Study 2904757 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 16 mg once daily)
Number of subjects: 67
Study 2904757 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 to 40 mg once daily)
Number of subjects: 67
Study 30803899 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐CFPD
Number of subjects: 21
Study 30803899 — intervention group
Group type: COMPARATOR
Intervention: MC‐CFPD
Number of subjects: 21
Study 27228002 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 246
Study 27228002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL) ovarian drilling
Number of subjects: 246
Study 25460267 — intervention group
Group type: EXPERIMENTAL
Intervention: Public speaking condition
Number of subjects: 0
Study 25460267 — intervention group
Group type: COMPARATOR
Intervention: Control (silent reading) condition
Number of subjects: 0
Study 23356862 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Caregivers‐Healthy Children (HC2) intervention
Number of subjects: 1105
Study 23356862 — intervention group
Group type: COMPARATOR
Intervention: Attention control safety curriculum (Control)
Number of subjects: 1105
Study 21716297 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin daily for 6 months
Number of subjects: 41
Study 21716297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 18642634 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital neurorehabilitation (4.9% of hospitalized TBI)
Number of subjects: 6783
Study 18642634 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital neurorehabilitation
Number of subjects: 6783
Study 18642634 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI severity, patient's age, concomitant organ lesions, and complications
Number of subjects: 6783
Study 17134628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 111
Study 17134628 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 111
Study 13130200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose fluticasone-salmeterol combination (FP/S)
Number of subjects: 0
Study 13130200 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids and long-acting B2-agonists given separately (TC)
Number of subjects: 0
Study 13130200 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FP/S and TC
Number of subjects: 0
Study 13130200 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerance
Number of subjects: 0
Study 11702613 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinol
Number of subjects: 15
Study 11702613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9176691 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (PHM) 7 gm, twice‐daily added to continuous feeding
Number of subjects: 60
Study 9176691 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (PHM) given as a bolus with intermittent feeding
Number of subjects: 60
Study 9176691 — intervention group
Group type: COMPARATOR
Intervention: No PHM for 7 days after initiation of enteral feeding
Number of subjects: 60
Study 1382251 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Aprotinin (two subgroups with different doses)
Number of subjects: 0
Study 1382251 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3891455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam Expidet 30 mg
Number of subjects: 72
Study 3891455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3891455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam Expidet
Number of subjects: 72
Study 30265572 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based inhibitory control training
Number of subjects: 19
Study 30265572 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 19
Study 30187935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 0.125 mg/kg
Number of subjects: 61
Study 30187935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 0.563 mg/kg
Number of subjects: 61
Study 30187935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 0.75 mg/kg
Number of subjects: 61
Study 30187935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 2.25 mg/kg
Number of subjects: 61
Study 30187935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (0.125, 0.563, or 0.75 mg/kg bid)
Number of subjects: 61
Study 30187935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30187935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 61
Study 27330010 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device
Number of subjects: 0
Study 27330010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25164709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing nomogram (65 patients)
Number of subjects: 131
Study 25164709 — intervention group
Group type: COMPARATOR
Intervention: Standard care (66 patients)
Number of subjects: 131
Study 22583459 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-6 algorithm
Number of subjects: 0
Study 22583459 — intervention group
Group type: EXPERIMENTAL
Intervention: MSQ algorithm
Number of subjects: 0
Study 22583459 — intervention group
Group type: COMPARATOR
Intervention: HIT-6 and MSQ algorithms
Number of subjects: 0
Study 20191258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formulation (NF) consisting of folic acid, B12, Vitamin E, S‐adenosylmethionine, N‐acetyl cysteine, and Acetyl‐L‐carnitine
Number of subjects: 0
Study 20191258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formulation (NF)
Number of subjects: 0
Study 20191258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18400837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity weight-bearing exercises
Number of subjects: 281
Study 18400837 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 281
Study 15800716 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy with mitomycin C and bleomycin
Number of subjects: 95
Study 12584669 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan treatment
Number of subjects: 3400
Study 12584669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3400
Study 11560727 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric hospital at home service (HAH)
Number of subjects: 40
Study 9397080 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg twice daily
Number of subjects: 113
Study 9397080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg once daily
Number of subjects: 113
Study 8215148 — intervention group
Group type: EXPERIMENTAL
Intervention: No touch technique
Number of subjects: 100
Study 8215148 — intervention group
Group type: COMPARATOR
Intervention: Hand in technique
Number of subjects: 100
Study 3826293 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow vergence training rate (0.75 delta/s)
Number of subjects: 18
Study 3826293 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast vergence training rate (5.00 delta/s)
Number of subjects: 18
Study 3826293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 18